Old Web
English
Sign In
Acemap
>
authorDetail
>
Thiagarajan Nambirajan
Thiagarajan Nambirajan
Belfast Health and Social Care Trust
Medicine
Rucaparib
Myosin light-chain kinase
Nitric oxide
PARP inhibitor
3
Papers
47
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself
2015
PLOS ONE
Cian M. McCrudden
Martin O'Rourke
Kim E Cherry
Hin-Fung Yuen
Declan O'Rourke
Muhammad Babur
Brian A. Telfer
Huw D. Thomas
Patrick F. Keane
Thiagarajan Nambirajan
Chris Hagan
Joe M. O’Sullivan
Christopher Shaw
Kaye J. Williams
Nicola J. Curtin
David G. Hirst
Tracy Robson
Show All
Source
Cite
Save
Citations (13)
The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria
2012
Cancer
Funso Abogunrin
Hugh F. O'Kane
Mark W. Ruddock
Michael Stevenson
Cherith N. Reid
Joe M. O’Sullivan
Neil H. Anderson
Declan O'Rourke
Brian Duggan
John Victor Lamont
Ruth Boyd
Peter Hamilton
Thiagarajan Nambirajan
Kate E. Williamson
Show All
Source
Cite
Save
Citations (33)
469: Initial PSA Levels and the Long-Term Risk of Prostate Cancer
2006
The Journal of Urology
David Connolly
Amanda Black
Thiagarajan Nambirajan
Liam Murray
Anna Gavin
Patrick F. Keane
Show All
Source
Cite
Save
Citations (1)
1